Phase 2
Completed N=9
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
Advanced Merkel Cell Carcinoma · Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 · Metastatic Merkel Cell Carcinoma
Source: ClinicalTrials.gov NCT03304639 ↗
Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Feb 2024
Primary outcomePrimary: Progression-free Survival (PFS) — 7.5; 5.5 months
Summary
This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with Merkel cell cancer that has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pembrolizumab with stereotactic body radiation therapy may work better in treating patients with Merkel cell cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival (PFS) |
7.5; 5.5 | — |
| SECONDARY PFS Among All Response Evaluation Criteria in Solid Tumors Lesions |
7.5; NA | — |
| SECONDARY Overall Response Rate |
1; 2 | — |
| SECONDARY Progression-free Survival |
1; 2 | — |
| SECONDARY Incidence of Adverse Events |
— | — |
| SECONDARY PFS for Lesions Chosen for Radiation Prior to Randomization |
— | — |
| SECONDARY Delivered Radiation Dose Using Cone-beam Computed Tomography (CT) Images |
24; 24; 16; 16 | — |
Eligibility Criteria
Inclusion Criteria
- Patients must have pathologically (histologically or cytologically) proven diagnosis of MCC by local pathology review
- Have measurable disease based on RECIST 1.1 including at least two cancerous deposits; at least one deposit must be RECIST measurable while at least one deposit must meet criteria for SBRT; non-radiated tumor will be identified prior to randomization on the protocol
- Patients must have advanced or metastatic MCC defined as evidence of distant metastasis(es) on imaging
- Patients with locoregionally confined disease are not eligible
- No prior immunotherapy for advanced/metastatic MCC
- Patients with known or suspected central nervous system (CNS) metastases, untreated CNS metastases, or with the CNS as the only site of disease are excluded; however, subjects with controlled brain metastases will be allowed to enroll; controlled brain metastases are defined as no radiographic progression for at least 4 weeks following radiation and/or surgical treatment (or 4 weeks of observation if no intervention is clinically indicated), and off of steroids for at least 2 weeks, and no new or progressive neurological signs and symptoms
- Patients having received palliative radiotherapy for extracranial metastasis(es) are eligible as long as there are 2 cancerous deposits that have not received prior radiation therapy (RT) and they meet the following criteria
- No prior radiation therapy (> 5 Gy) to the metastasis intended to be treated with SBRT
- No history of the following:
- Autoimmunity requiring systemic immunosuppression within 2 years
- Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following:
- CD4 counts >= 350 mm^3
- Serum HIV viral load of = 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin >= 9.0 g/dl
- Total bilirubin = 3 mg/dl
- Blood urea nitrogen (BUN) =< 30 mg/dl
- Creatinine =< 1.7 mg/dl
- The following imaging workup to document metastases within 45 days prior to study registration are required: CT scans of the chest, abdomen and pelvis with radionuclide bone scan OR whole body (at least skull base to midthigh) positron emission tomography (PET)/CT
Data sourced from ClinicalTrials.gov (NCT03304639). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.